Get the Stockscreener App
1.58
1.28%
0.02
Macrogenics Inc stock is traded at $1.58, with a volume of 1.05M.
It is up +1.28% in the last 24 hours and up +25.40% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.56
Open:
$1.49
24h Volume:
1.05M
Relative Volume:
0.89
Market Cap:
$99.68M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.00
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-7.60%
1M Performance:
+25.40%
6M Performance:
-47.33%
1Y Performance:
-60.50%
1-Day Range:
$1.49
$1.62
1-Week Range:
$1.47
$1.76
52-Week Range:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.58 | 98.42M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
What makes MacroGenics Inc. stock price move sharplyOutstanding stock performance - jammulinksnews.com
What are MacroGenics Inc. company’s key revenue driversHigh-yield investments - jammulinksnews.com
Is MacroGenics Inc. a growth stock or a value stockSuperior return velocity - jammulinksnews.com
How volatile is MacroGenics Inc. stock compared to the marketExceptional trading results - jammulinksnews.com
What are the latest earnings results for MacroGenics Inc.Grow your wealth with proven stock picks - jammulinksnews.com
How strong is MacroGenics Inc. company’s balance sheetEntry Signal Growth Plan For Every Investor - jammulinksnews.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
What institutional investors are buying MacroGenics Inc. stockPost Market Opportunities With High Returns - jammulinksnews.com
MacroGenics’ Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Why MacroGenics Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - metal.it
MacroGenics’ Phase 2 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
RSI and MACD Indicate Shift in MacroGenics Inc. SentimentProven Entry Plan With Low Risk Shared - metal.it
Is MacroGenics Inc. Starting a New UptrendBuy Low Sell High Stock Watch Strategy in Focus - metal.it
MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks
Will MacroGenics Inc. see short term momentumWeekly Trend Watch with Market Signals - Newser
What the charts say about MacroGenics Inc. todayGrowth Summary Based on Market Positioning - Newser
Analyzing MacroGenics Inc. with multi timeframe chartsFree Trend Following Strategy With Stop Loss - Newser
How does MacroGenics Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - jammulinksnews.com
What catalysts could drive MacroGenics Inc. stock higher in 2025Invest confidently with real-time market updates - jammulinksnews.com
What is MacroGenics Inc. company’s growth strategyRealize consistent double-digit growth - jammulinksnews.com
Why is MacroGenics Inc. stock attracting strong analyst attentionAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
When is MacroGenics Inc. stock expected to show significant growthUnstoppable trading performance - jammulinksnews.com
How MacroGenics Inc. stock performs during market volatilityProven Return Strategy Execution - metal.it
Moving Average Trends for MacroGenics Inc. Stock: What They IndicateElite Stock Shortlist - Newser
MacroGenics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Access to Investment Community - Newser
Is MacroGenics Inc. stock a good hedge against inflationFree Growth Investment Group - Newser
MacroGenics Inc. Stock Analysis and ForecastTremendous financial leverage - PrintWeekIndia
What drives MacroGenics Inc. stock priceExceptional earning trajectories - Autocar Professional
What analysts say about MacroGenics Inc. stockHigh-octane investment gains - PrintWeekIndia
Is MacroGenics Inc. a good long term investmentMarket-crushing profits - Autocar Professional
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of “Hold” by Brokerages - Defense World
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):